Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid Pabinger

Showing results (51-60 of 367) with videos related to

Pageof 37
Sort By:
Thrombosis Research|September 29, 2014
Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one yearJohannes Thaler, Renate Koppensteiner, Ingrid Pabinger, et al.
Thrombosis Research|July 27, 2015
Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulantsFlorian Posch, Oliver Königsbrügge, Christoph Zielinski, et al.
Annals of Hematology|May 10, 2011
Platelet activation and function during eltrombopag treatment in immune thrombocytopeniaJohanna Haselboeck, Ingrid Pabinger, Cihan Ay, et al.
Thrombosis Research|April 29, 2018
The role of podoplanin in cancer-associated thrombosisPegah Mir Seyed Nazari, Julia Riedl, Ingrid Pabinger, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|August 27, 2013
Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formationJohannes Thaler, Silvia Koder, Gabriela Kornek, et al.
Annals of Hematology|September 12, 2020
Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world settingCihan Ay, Leonard Perschy, Judit Rejtö, et al.
BMC Cardiovascular Disorders|December 13, 2016
Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registryOliver Königsbrügge, Alexander Simon, Hans Domanovits, et al.
Wiener Klinische Wochenschrift|April 23, 2017
Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysisIngrid Pabinger, Dietmar Fries, Herbert Schöchl, et al.
Annals of Hematology|March 2, 2011
Thrombin generation in patients with a bleeding tendency of unknown originCihan Ay, Johanna Haselböck, Clarissa Laczkovics, et al.
European Journal of Internal Medicine|March 12, 2021
Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillationStephan Nopp, Oliver Königsbrügge, Daniel Kraemmer, et al.
Pageof 37

Showing results (51-60 of 367) with videos related to

Sort By:
Pageof 37
Thrombosis Research|September 29, 2014
Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one yearJohannes Thaler, Renate Koppensteiner, Ingrid Pabinger, et al.
Thrombosis Research|July 27, 2015
Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulantsFlorian Posch, Oliver Königsbrügge, Christoph Zielinski, et al.
Annals of Hematology|May 10, 2011
Platelet activation and function during eltrombopag treatment in immune thrombocytopeniaJohanna Haselboeck, Ingrid Pabinger, Cihan Ay, et al.
Thrombosis Research|April 29, 2018
The role of podoplanin in cancer-associated thrombosisPegah Mir Seyed Nazari, Julia Riedl, Ingrid Pabinger, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|August 27, 2013
Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formationJohannes Thaler, Silvia Koder, Gabriela Kornek, et al.
Annals of Hematology|September 12, 2020
Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world settingCihan Ay, Leonard Perschy, Judit Rejtö, et al.
BMC Cardiovascular Disorders|December 13, 2016
Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registryOliver Königsbrügge, Alexander Simon, Hans Domanovits, et al.
Wiener Klinische Wochenschrift|April 23, 2017
Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysisIngrid Pabinger, Dietmar Fries, Herbert Schöchl, et al.
Annals of Hematology|March 2, 2011
Thrombin generation in patients with a bleeding tendency of unknown originCihan Ay, Johanna Haselböck, Clarissa Laczkovics, et al.
European Journal of Internal Medicine|March 12, 2021
Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillationStephan Nopp, Oliver Königsbrügge, Daniel Kraemmer, et al.
Pageof 37